Incyte, Merck melanoma combo therapy fails study, shares slide

(Reuters) – Incyte Corp said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck & Co’s Keytruda failed to meet the main goal in a late-stage study.

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *